| Added by | liaudet-coopman |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model |
| Creator | Trédan et al. |
| Author | Magali Lacroix-Triki |
| Author | Séverine Guiu |
| Author | Marie-Ange Mouret-Reynier |
| Author | Jérôme Barrière |
| Author | François-Clément Bidard |
| Author | Antoine-Laurent Braccini |
| Author | Olivier Mir |
| Author | Christian Villanueva |
| Author | Philippe Barthélémy |
| Abstract | Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. Antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. According to Jain et al., an alternative hypothesis could be that certain antiangiogenic agents can also transiently "normalize" the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. With emphasize on the research works of Jain et al., the aim of this review is to describe the impact of antivascular endothelial growth factor (VEGF) therapy on "pseudo-normalization" of tumor vasculature and tumor microenvironment, its role in early and metastatic breast cancer, and the clinical evidence supporting this original concept. The phase III clinical trials showed that extended tumors, metastatic or locally advanced, are likely to benefit from bevacizumab therapy in combination with chemotherapy, assuming that a high level of tumor neoangiogenesis as in triple-negative tumors is the best target. In adjuvant setting, the lower level of tumor vasculature could mask a potential benefit of anti-VEGF therapy. All these findings highlight the need to identify biomarkers to help in the selection of patients most likely to respond to anti-VEGF therapy, to better understand the mechanism of angiogenesis and of resistance to anti-VEGF therapy according to molecular subtypes. |
| Publication | Targeted Oncology |
| Volume | 10 |
| Issue | 2 |
| Pages | 189-198 |
| Date | Jun 2015 |
| Journal Abbr | Target Oncol |
| Language | eng |
| DOI | 10.1007/s11523-014-0334-9 |
| ISSN | 1776-260X |
| Short Title | Angiogenesis and tumor microenvironment |
| Library Catalog | PubMed |
| Extra | PMID: 25185646 |
| Tags | Angiogenesis Inhibitors, Animals, Bevacizumab, Biomarkers, Tumor, Breast Neoplasms, clinic, Drug Resistance, Neoplasm, Female, Humans, Neovascularization, Pathologic, Patient Selection, Predictive Value of Tests, Signal Transduction, Tumor Microenvironment, Vascular Endothelial Growth Factor A |
| Date Added | 2018/09/26 - 14:32:50 |
| Date Modified | 2019/05/29 - 12:08:49 |
Institut de Recherche en Cancérologie de
